Reimagining Medicine
Company overview
Financial review
Conclusions
Appendix
References
FINANCIAL PROFILE
Very strong H1; Q2 continuing robust top and bottom-line growth...
Group¹
USD million
Q2
2023
Change vs. PY
H1
Change vs. PY
% USD
% CC
2023
% USD
% CC
Net Sales
13,622
7
9
26,575
5
8
Core Operating income
4,668
9
17
9,081
9
16
Operating income
2,920
31
50
50
5,776
14
28
Net Income
2,317
37
54
4,611
18
Core EPS (USD)
1.83
17
25
3.54
17
EPS (USD)
1.11
44
62
2.20
24
39
32
25
39
32
25
Free Cash Flow
3,275
-6
5,995
23
1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 48 of the Condensed Interim Financial Report.
19 Investor Relations | Q2 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation